title: Antagonism of endogenous mineralocorticoids in normal subjects by prorenoate potassium and spironolactone.
abstract: The pharmacological activity of single oral doses of a new aldosterone antagonist, prorenoate potassium, has been compared with spironolactone and placebo in a balanced double-blind crossover study in six healthy subject. Endogenous mineralocorticoids were stimulated by administration of frusemide followed by dietary sodium restriction, and the urinary excretion of electrolytes in response to prorenoate potassium, spironolactone and placebo was measured over a 24 hour period. Significant activity of prorenoate potassium and spironolactone was observed between 2 - 24 hours after medication, with peak activity at 6 - 8 hours. The active drugs significantly increased sodium excretion and the sodium : potassium (Na/K) ratio, but changes in potassium excretion were not significant. The total urine Na/K response to prorenoate potassium 45 mg was significantly greater than to spironolactone 100 mg.
mesh_terms: D000328:Adult; D002191:Canrenoic Acid / Q000031:analogs & derivatives / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004231:Diuresis / Q000187:drug effects; D005665:Furosemide / Q000494:pharmacology; D006801:Humans; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists; D010919:Placebos; D011188:Potassium / Q000652:urine; D011245:Pregnadienes / Q000494:pharmacology*; D011283:Pregnenes / Q000009:adverse effects / Q000494:pharmacology*; D012964:Sodium / Q000652:urine; D013148:Spironolactone / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D010919:Placebos; D011245:Pregnadienes; D011283:Pregnenes; D013148:Spironolactone; D005665:Furosemide; D002191:Canrenoic Acid; D012964:Sodium; D011188:Potassium